Sartorius

4y

Sartorius Stedim Biotech has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders.

Sartorius

4y

“When you’re ambitious and passionate, opportunities are everywhere”, says Peter Fu, who joined Sartorius in 2014 and now ensures that production processes at our Chinese customers’ sites run smoothly. Find out how he has built his ideal career alongside the growth of the company and what he thinks is special about Sartorius.

Sartorius

4y

Sartorius acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines. It has so far been privately owned and employs around 35 people.

Sartorius

5y

Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.

Sartorius

5y

Sartorius looks and feels different today than it did one and a half years ago. Over the past decade, the company has grown and changed significantly. Finally in 2020, we launched our sharpended brand, that now revolves around our promise "Simplifying Progress". Since then, the Sartorius Coprorate Branding and Design Team was honored with a series of branding awards for this successful transformation. Read more about the ideas and concepts behind Sartorius brand, along with the latest award wins: https://bit.ly/3r7k7OV

Sartorius

5y

Sartorius announces today that it expects strong first half performance and raises its forecast for the full year of 2021. For the first six months ended June 30, the company expects revenue growth to be approximately 60% in constant currencies with an underlying EBITDA margin slightly above 34.0%.

Sartorius

5y

Sartorius has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, with around 70 employees produces and markets cell culture components, such as growth factors, cytokines, and media. Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.

Sartorius

5y

What does a company need to be innovative? Read the interview to find out why our Head of Research and CTO Oscar-Werner Reif believes that the crucial factor is the people, not the money – and how he wins over talented people to work for Sartorius.

Sartorius

5y

Sartorius is expanding its manufacturing capabilities in Israel. Today, we opened a new 11,800-square-foot production facility in Beit Haemek and the upgraded facility already in place. The new site enables the production of advanced cell culture media, particularly for the advanced therapies market. Watch the guided tour of the facility and meet our Beit Haemek team.

Sartorius

5y

Sartorius is expanding its production capabilities in Slovenia. The expanded site in Ajdovscina will contribute to the development and #manufacturing of market-leading products for #purification and analysis of large biomolecules, such as viruses, plasmids and #mRNA. These are used in vaccines as well as in cell and gene therapies and other advanced therapies.